Central Admixture Pharmacy Services, Phoenix, AZ
Is Central Admixture Pharmacy Services registered with the FDA as a 503B outsourcing facility?
Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Central Admixture Pharmacy Services in Phoenix, AZ, first registered Mar 29, 2018 and most recently registered Nov 21, 2025.
Does Central Admixture Pharmacy Services hold a Arizona pharmacy license?
State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks. The California State Board of Pharmacy also lists nonresident license NSF 130 for Central Admixture Pharmacy Services Inc, Phoenix, AZ, status Delinquent, as of Nov 6, 2026. The Delaware Division of Professional Regulation also lists nonresident license AD-0010071 for Central Admixture Pharmacy Services, Inc., PHOENIX, AZ, status Closed, as of Nov 10, 2026.
Has Central Admixture Pharmacy Services had a state board action or FDA letter?
FDA letters: no matching record found. No entry for Central Admixture Pharmacy Services was matched by name and location on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026. The page does list Central Admixture Pharmacy Services, Inc. in Phoenix, AZ, a close but not exact match shown below. State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses also lists 2 actions: “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for three years subject to the terms and conditions in the decision” dated Jan 7, 2026, case AC 7634 on nonresident license NSF 130 and “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for three years subject to the terms and conditions in the decision” dated Jan 7, 2026 on nonresident license NSF 130.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Central Admixture Pharmacy Services
- Location
- Phoenix, AZ
- Type as FDA labels it
- 503B
- FDA 503B list
- Listed as Central Admixture Pharmacy Services
- Form 483s on FDA’s actions page
- 0
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- None listed
- FDA Data Dashboard inspections
- 4 inspections: 2 OAI, 1 VAI, 1 NAI; 3 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 14 observations
- State board records
- Not checked
FDA inspections and letters
No entry for this name and location was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). That page covers actions from 2019 on; FDA keeps earlier ones in its archive.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Central Admixture Pharmacy Services, Inc., Phoenix, AZ (FEI number 3014307835), matched to this page by exact name, city and state. It lists 4 inspections: 2 OAI, 1 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Sep 5, 2025 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3014307835 | 1266983 |
| Jul 31, 2023 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3014307835 | 1215605 |
| Feb 25, 2022 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3014307835 | 1163112 |
| Apr 26, 2019 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3014307835 | 1092112 |
Form 483s FDA has published for this site
- Sep 5, 2025: Form 483 to Central Admixture Pharmacy Services, Inc., published Dec 1, 2025. fda.gov
- Jul 31, 2023: Form 483 to Central Admixture Pharmacy Services, Inc., published Nov 15, 2023. fda.gov
- Feb 25, 2022: Form 483 to Central Admixture Pharmacy Services, Inc., published Jun 13, 2022. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 14 numbered observations in all, across 2 inspections ending Feb 25, 2022 to Sep 5, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 18, 2025 to Sep 5, 2025: 8 observations
- Firm on the cover
- Central Admixture Pharmacy Services, Inc., 2200 S 43rd Ave, Phoenix, AZ 85043-3909
- FEI number
- 3014307835
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 6th & Kipling St. (P.O. Box 25087)Denver, CO 80225-0087
- Matched to this page by
- FEI number on the cover; linked from 503B list, actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
The firm has failed to ensure reliable and reproducible quality production of sterile drug products manufactured by admixture compounding of active ingredients into intravenous (IV) bags and syringes and released to market. The firm has reported recurring non-conformances (NC) and notice of quality events (NQE) from July 2023 to August 2025 for defective units of IV bag drug products. Defects include particulate matter in solution (PM-S), particulates embedded (PM-E), delamination of external layer of IV bag, uncapped or leaky IV injection ports, leaking bag, defective component, or damaged labels.
A. From April 2024 -August 2025, over 212 out of 1096 non-conformances (20%) were for failed 1st or 2nd Acceptable Quality Limit (AQL) visual inspection for particulate matter (PM-S and PM-E) inside the bags. Additionally, your firm reported 30 non-conformances for delamination or crinkles in the outer plastic lining ofthe IV bags for the same period. ...
Observation 2
Component testing is deficient in that each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.
Specifically,
Each batch of diluent IV bags including Normal Saline (NS), 5% Dextrose in Water (D5W), and other diluents, are not tested by 100% visually inspection, strict AQL visual inspection, or other Quality Control tests to ensure the materials are free of foreign particles and meet the specifications of sterility, endotoxin, and other specifications, prior to adding drug products such as Heparin, Oxytocin, Phenylephrine, or other drugs. Change request CR-04984 has been recently initiated in August 2025 to create an Incoming Inspection SOP. SOP-CAPS-4000530, for Material Receiving, Handling, and Storage -503B covers the initial receiving and shipment inspection in the warehouse but there is no procedure or current process developed yet at the firm to complete 100% visual inspection of the IV diluent bags prior to use in compounding. ...
Observation 3
The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.
Specifically,
A. The firm failed to demonstrate reproducibility of the <Redacted B4> Microbial Detection System used for sterility testing of drug products compounded in IV bags and syringes. The firm's <Redacted B4> Microbial Detection System Results Performance Qualification (PQ) for Sterility Testing of CAPS Products Summary Report" #V0184 was generated by testing drug product in the presence of ATCC organisms. This performance qualification was done with <Redacted B4> samples from <Redacted B4> in <Redacted B4> by <Redacted B4> on <Redacted B4> with <Redacted B4>. This validation was performed by and approved your Quality Validation Manager on 10/18/2019. Additionally, the environmental isolate used as representative flora during the method validation was an environmental isolate from the CAPS <Redacted B4> in <Redacted B4> not the actual 503B production site in Phoenix, AZ.
B. The <Redacted B4> Microbial Detection System is designed to warn the user of microbial growth via the generation of CO2 as a biproduct of microbial metabolism. ...
Observation 4
Written records of investigations into the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up.
Specifically,
Your firm failed to thoroughly investigate three <Redacted B4> Microbial Detection System sterility test failures (OOS-00055, OOS-00070, & OOS-00104) for Heparin 4000 units/1000 mL NS (NDC: 7022-1) between 04/2025 and 06/2025. Investigations into these discrepancies included review of materials used and employee interviews. The isolates recovered were identified as Bacillus circulans in April and Chaetomium globosum between 05/2025 & 06/2025. The investigations failed to address any aspects downstream of production, but not limited to, visual inspection, sample chain of custody, and media sterility.
Observation 5
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Specifically,
The firm's Quality Unit is not taking effective measures to respond to discrepancies in materials, production, inspection, and other systems to ensure consistent, reliable, quality products are made for market distribution.
A. The firm's Quality Procedures, Quality Unit, and Site Leadership are new with personnel in leadership positions at the site for less than 1 year. The firm had multiple quality system restarts between 2023-2025. The firm has used 2-3 databases for recording Notice of Quality Events (NQE), Nonconformances (NC), Out of Specifications (OOS), Complaints/ Adverse Drug Events (ADEs), change controls, and deviation investigations (DEV), and other quality events. The firm's management has reported that procedures for quality oversight of the firm have been evolving between 2023-2025. Trending of quality evens has been inconsistent from customer service reports that only include select limited number of quality events ;<Redacted B4> to [(6)(4} I Quality System Management Reviews that only start from January 2025 to present. ...
Observation 6
Established standards, sampling plans and test procedures are not followed.
Specifically,
A. Per the firm' s management and non-conformance investigations, the firm's finished product visual inspection test procedure, SOP-CAPS-4000688, is deficient and not fully followed. This visual inspection test procedure, SOP-CAPS-4000688, states that inspectors will have inute break after utes of product inspection. DEV-001194 opened on 6/24/2025 considered changing the inspection time to 30 minutes with a 5 minute break, but the inspection procedure has not been updated. Non-conformance NC-10409, 7/02/2025, states that Heparin 4,000 Units/ I 000 mL NS, batch 36-276932, had 2 visual inspection sessions that exceeded the <Redacted B4> minute maximum for continuous visual inspection.
B. Per the firm's management, the environment for Visual Inspection and Labeling Area (VILA) in an IS0-8 corridor and the AQL visual inspection area in the warehouse are deficient and do not allow optimal inspection to detect particles and other defects in IV bags and syringes. ...
Observation 7
Establishment of the reliability ofvthe component supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.
Specifically,
The firm does not have a procedure for supplier material verification testing. The firm does not perform quality control testing at least annually to confirm specifications, including purity, potency, sterility, and other specifications, to confirm the material Certificate of Analysis and verify the supplier reliability for drug active ingredients used for admixture compounding of finished drugs in IV bags and syringes, including but not limited to, Heparin, Oxytocin, Phenylephrine, Lidocaine, Rocuronium Bromide, and other drug active ingredients. Supplier qualification and reporting is deficient to ensure that all starting materials conform to specifications prior to use in production.
Observation 8
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
The firm's procedure SOP-CAPS-4000820, 7.0, 12/15/2024, <Redacted B4> Continuous Environmental Monitoring System Operation is deficient in that it allows the use of manual non-viable and viable active air environmental monitoring equipment to be used in the event of a system failure for the <Redacted B4> Continuous EM monitoring. The manual non-viable and viable active air environmental monitoring equipment do not operate continuously and do not monitor the entire aseptic compounding operation.
Inspection Feb 14, 2022 to Feb 25, 2022: 6 observations
- Firm on the cover
- Central Admixture Pharmacy Services, Inc., 2200 s 43rd Ave, Phoenix, AZ 85043-3909
- FEI number
- 3014307835
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 6t h & Kipling St. (P.O. Box 25087) Denver, co 80225-0087
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Specifically,
A. Your firm failed to include the large red container as used under dynamic conditions during normal operations. On 02/18/22, during production of Rocuronium 10 mg/ml 5 ml syringes, lot RN I, we observed a large red container placed in the middle of the ISO 5 hood where the sterile operator was performing aseptic manipulations. The large red container was being used as a catch bin for caps being removed from vials. The large red container was not included in the smoke study conducted on 05/22/21 as part of the qualification of the ISO 5 hoods.
B. Your fnm failed to demonstrate laminar· airflow during the qualification of your ISO 5 hoods based on your smoke studies. During the review of the smoke study video provided during the inspection with file name <Redacted B4>, dated 05/22/21, we observed multiple instances of turbulent airflow around equipment and materials inside the ISO 5 hoods. The turbulent airflow was observed under static and dynamic conditions. ...
Observation 2
Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
Specifically, your firm does not adequately maintain your ISO 5 hoods used to produce sterile drug products. On 02/16/22 and 02/18/22, we observed scratches on the back wall of the ISO 5 hoods during production of del Nido Formula (Plasmalyte) 1052.8 ml, lot RN I, and Rocuronium 10 mg/ml 5 ml syringes, lot <Redacted B4>, respectively. The scratched surfaces do not appear to be smooth and easily cleanable for aseptic operations.
Laboratory System
Observation 3
Laboratory records do not include a record of all calculations performed in connection with the test.
Specifically, your firm failed to establish an adequate written procedure that specifies how to calculate assay results for retesting amino acids. Written procedure titled Amino Acid Analysis Test, number <Redacted B4> version 4.0, effective date 05/24/21, section 14.6 reporting results, states <Redacted B4>. On 02/22/22, your Chemist Team Lead stated she does not record the calculations and cannot recall how the calculations were performed to release Trophamine 4%/Dextrose 10% w/ Ca Gluc and Heparin, 250 ml, lot <Redacted B4>, and finished product Trophamine 4%/Dextrose 10%, 250 ml, lot <Redacted B4>. The Chemist Team Lead demonstrated at least two ways to perform the calculation that might have been used; however, one of the demonstrated ways showed an out-of-specification (OOS) result. Total Parenteral Nutrition (TPN) products that require retesting to invalidate an OOS uses this calculation. There is no guarantee after assay testing that reported results are accurate for the release of finished sterile drug products. ...
Observation 4
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
Specifically,
A. Your firm failed to adequately control finished product assay testing data. On 02/16/22, we observed the Chemist Team Lead having unrestricted privileges, including creating and deleting data, on the I software. The <Redacted B4> software is used to capture finished product assay results used to release finished sterile drug products.
B. Your firm failed to adequately control adjustments to the date and times recorded on your assay testing data. On 02/16/22, we observed the date and time could be altered on Ultra Performance Liquid Chromatography (UPLC) data by changing the computer system's date and time. There are no controls in place to prevent laboratory personnel from altering the date and time on UPLC data used to release finished sterile drug products.
Facilities and Equipment System
Observation 5
Equipment and utensils are not maintained at appropriate intetervals to prevent malfunctions that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, your firm failed to maintain the <Redacted B4>, system used for sterility testing. On 02/17 /22, we observed the <Redacted B4>, system, asset ID # , being past due for calibration. The system was installed on 01/15/2021 with an calibration interval of from installation. The <Redacted B4> system is used for sterility testing for all finished sterile drug products.
Quality System
Observation 6
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been aheady distributed.
Specifically, your firm failed to follow your written procedure titled Notification of Quality Events, number SOP-CAPS-4000693, version 10.0, effective date 11/08/21 , used for reporting and documenting quality events.
For example, we observed NQE reports related to particles in solution and yield percentage stating tracking and trending was performed; however, no adequate data was available for review during the inspection. Also, 10 out of 12 NQE reports related to complaints exceeded due dates without adequate justification.
The quality system for reporting and documenting quality issues is out of control.
State board of pharmacy records
State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
California State Board of Pharmacy, file dated Nov 6, 2026 (California).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| NSF 130 | Nonresident Outsourcing Facility | Central Admixture Pharmacy Services Inc | Phoenix, AZ | Delinquent |
- Jan 7, 2026: “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for three years subject to the terms and conditions in the decision.”, license NSF 130, case AC 7634, Central Admixture Pharmacy Services Inc., Phoenix, AZ. Board list
- Jan 7, 2026: “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for three years subject to the terms and conditions in the decision.”, license NSF 130, Central Admixture Pharmacy Services Inc., Phoenix, AZ. Board list
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| AD-0010071 | Outsourcing Facility-Distributor | Central Admixture Pharmacy Services, Inc. | PHOENIX, AZ | Closed |
FDA’s 503B list
- Central Admixture Pharmacy Services, Phoenix, AZ: last inspection Sep 5, 2025, Form 483 at that inspection: Yes, action FDA lists: Regulatory Meeting Held 5/5/2026.
Close but not exact matches
These FDA records share a name or a former name with this pharmacy but did not meet this index’s matching rule (the same legal name with the same legal ending, in the same city and state), so they are kept on their own pages. Check them against the pharmacy you are looking for.
- Central Admixture Pharmacy Services, Inc., Phoenix, AZ: same city and state; names match only without the legal ending or through a dba name.
Same name at other locations
FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- California State Board of Pharmacy license file
- Delaware Division of Professional Regulation license file
- California State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.